501358-54-9

Basic information

• Product Name: 4,6-dichloro-3H-[1,2,3]triazolo[4,5-c]pyridine
• Synonyms: 4,6-dichloro-3H-[1,2,3]triazolo[4,5-c]pyridine
• CAS NO: 501358-54-9
• Molecular Formula: C₅H₂Cl₂N₄
• Molecular Weight: 189.00218
• Mol File: 501358-54-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,6-dichloro-3H-[1,2,3]triazolo[4,5-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dichloro-3H-[1,2,3]triazolo[4,5-c]pyridine(501358-54-9)
• EPA Substance Registry System: 4,6-dichloro-3H-[1,2,3]triazolo[4,5-c]pyridine(501358-54-9)

Safety Data

• Hazardous Substances Data: 501358-54-9(Hazardous Substances Data)

Upstream product

• 2897-43-0 2,6-dichloro-3-nitropyridin-4-amine 
• 2587-02-2 2,6-dichloro-[4]pyridylamine 
• 101079-63-4 3,4-diamino-2,6-dichloropyridine 

Downstream Products

• 579486-74-1 3-(5-methoxypentyl)-7-(3,4-dichlorobenzylamino)triazolo[4,5-c]pyridine-2-one 
• 579486-71-8 4-benzyloxy-6-chloro-1,2,3-triazolo[4,5-c]pyridine 

Relevant articles and documents

Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

Src homology 2 (SH2) domain-containing phosphatase 2 (SHP2) plays a role in receptor tyrosine kinase (RTK), neurofibromin-1 (NF-1), and Kirsten rat sarcoma virus (KRAS) mutant-driven cancers, as well as in RTK-mediated resistance, making the identification of small-molecule therapeutics that interfere with its function of high interest. Our quest to identify potent, orally bioavailable, and safe SHP2 inhibitors led to the discovery of a promising series of pyrazolopyrimidinones that displayed excellent potency but had a suboptimal in vivo pharmacokinetic (PK) profile. Hypothesis-driven scaffold optimization led us to a series of pyrazolopyrazines with excellent PK properties across species but a narrow human Ether-à-go-go-Related Gene (hERG) window. Subsequent optimization of properties led to the discovery of the pyrimidinone series, in which multiple members possessed excellent potency, optimal in vivo PK across species, and no off-target activities including no hERG liability up to 100 μM. Importantly, compound 30 (IACS-15414) potently suppressed the mitogen-activated protein kinase (MAPK) pathway signaling and tumor growth in RTK-activated and KRASmut xenograft models in vivo.

CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY

Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.

7-Alkyl-N2-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity

Several 2-anilino- and 2-benzylamino-3-deaza-6-oxopurines [3-deazaguanines] and selected 8-methyl and 8-aza analogs have been synthesized. 7-Substituted N2-(3-ethyl-4-methylphenyl)-3-deazaguanines were potent and selective inhibitors of Gram+ bacterial DNA polymerase (pol) IIIC, and 7-substituted N2-(3,4-dichlorobenzyl)-3-deazaguanines were potent inhibitors of both pol IIIC and pol IIIE from Gram+ bacteria, but weakly inhibited pol IIIE from Gram- bacteria. Potent enzyme inhibitors in both classes inhibited the growth of Gram+ bacteria (MICs 2.5-10 μg/ml), and were inactive against the Gram- organism Escherichia coli. Several derivatives had moderate protective activity in Staphylococcus aureus-infected mice.